JP2024540148A5 - - Google Patents
Info
- Publication number
- JP2024540148A5 JP2024540148A5 JP2024525546A JP2024525546A JP2024540148A5 JP 2024540148 A5 JP2024540148 A5 JP 2024540148A5 JP 2024525546 A JP2024525546 A JP 2024525546A JP 2024525546 A JP2024525546 A JP 2024525546A JP 2024540148 A5 JP2024540148 A5 JP 2024540148A5
- Authority
- JP
- Japan
- Prior art keywords
- sequence shown
- seq
- variable region
- amino acid
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111305149 | 2021-11-05 | ||
| CN202111305149.7 | 2021-11-05 | ||
| PCT/CN2022/129803 WO2023078382A1 (zh) | 2021-11-05 | 2022-11-04 | 结合gprc5d的抗体及其用途 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024540148A JP2024540148A (ja) | 2024-10-31 |
| JP2024540148A5 true JP2024540148A5 (https=) | 2025-11-12 |
Family
ID=86240662
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024525546A Pending JP2024540148A (ja) | 2021-11-05 | 2022-11-04 | Ｇｐｒｃ５ｄに結合する抗体及びその使用 |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP4428153A4 (https=) |
| JP (1) | JP2024540148A (https=) |
| KR (1) | KR20240099351A (https=) |
| CN (1) | CN118159565A (https=) |
| TW (1) | TW202334222A (https=) |
| WO (1) | WO2023078382A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116925229B (zh) * | 2023-09-19 | 2023-12-15 | 南京驯鹿生物技术股份有限公司 | 一种靶向gprc5d的抗体及其应用 |
| US20250127728A1 (en) | 2023-10-05 | 2025-04-24 | Capstan Therapeutics, Inc. | Constrained Ionizable Cationic Lipids and Lipid Nanoparticles |
| WO2025076113A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Ionizable cationic lipids with conserved spacing and lipid nanoparticles |
| WO2025217452A1 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| WO2025217454A2 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Ionizable cationic lipids and lipid nanoparticles |
| US12545726B1 (en) | 2025-07-22 | 2026-02-10 | Integral Molecular, Inc. | Compositions and methods related to GPRC5D binding agents and variants thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112017011932A8 (pt) * | 2014-12-05 | 2022-11-08 | Memorial Sloan Kettering Cancer Center | Anticorpos direcionados a receptor acoplado a proteína g e métodos de uso |
| TWI781108B (zh) * | 2016-07-20 | 2022-10-21 | 比利時商健生藥品公司 | 抗ｇｐｒｃ５ｄ抗體、結合ｇｐｒｃ５ｄ與ｃｄ３之雙特異性抗原結合分子及其用途 |
| SG11201907321TA (en) * | 2017-02-07 | 2019-09-27 | Daiichi Sankyo Co Ltd | Anti-gprc5d antibody and molecule comprising the antibody |
| TWI829667B (zh) * | 2018-02-09 | 2024-01-21 | 瑞士商赫孚孟拉羅股份公司 | 結合gprc5d之抗體 |
| BR112021013824A2 (pt) * | 2019-01-18 | 2021-12-14 | Janssen Biotech Inc | Receptores de antígeno quiméricos gprc5d e células que expressam os mesmos |
| CA3248329A1 (en) * | 2019-07-31 | 2025-11-29 | F. Hoffmann-La Roche Ag | Antibodies binding to gprc5d |
-
2022
- 2022-11-04 CN CN202280073069.XA patent/CN118159565A/zh active Pending
- 2022-11-04 KR KR1020247017404A patent/KR20240099351A/ko active Pending
- 2022-11-04 EP EP22889403.6A patent/EP4428153A4/en active Pending
- 2022-11-04 WO PCT/CN2022/129803 patent/WO2023078382A1/zh not_active Ceased
- 2022-11-04 TW TW111142114A patent/TW202334222A/zh unknown
- 2022-11-04 JP JP2024525546A patent/JP2024540148A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024540148A5 (https=) | ||
| CA2987118C (en) | A pdl-1 antibody, pharmaceutical composition thereof and use thereof | |
| JP2022177090A5 (https=) | ||
| JP2021531005A5 (https=) | ||
| JP2022533538A5 (https=) | ||
| JP2021533726A5 (https=) | ||
| JP2021516974A5 (https=) | ||
| CN101516394B (zh) | 制备抗耐药性抗原的活性抗体的方法、所述方法获得的抗体及其用途 | |
| HRP20120701T1 (hr) | Humana monoklonska protutijela protiv fukozil-gm1 i postupci za uporabu antifukozil-gm1 | |
| JP2022523442A5 (https=) | ||
| CN110536903A (zh) | 抗ox40抗体及其用途 | |
| JP2020522280A5 (https=) | ||
| RU2019121086A (ru) | Иммунотерапия с применением антител, связывающих лиганд 1 белка программируемой смерти клеток (PD-L1) | |
| JP2020522281A5 (https=) | ||
| JP2020514277A5 (https=) | ||
| CN112513094A (zh) | 结合人her2的抗体、其制备方法和用途 | |
| JP2024024114A5 (https=) | ||
| WO2022105914A1 (zh) | Cd70抗体及其应用 | |
| AU2022332499A1 (en) | Fap/cd40 binding molecule and medicinal use thereof | |
| JP2023522730A5 (https=) | ||
| CN115812081A (zh) | 抗ctla-4抗体及其用途 | |
| JP2023545182A5 (https=) | ||
| RU2019135404A (ru) | Антитела для лечения инфекции гепатитом в и связанных с ней заболеваний | |
| JP2024516098A5 (https=) | ||
| CN111712521A (zh) | Cd38蛋白抗体及其应用 |